Last updated: February 20, 2026
What is the Drug with NDC 82009-0087?
The drug identified by NDC 82009-0087 is Jevtana (cabazitaxel) injection. It is an antineoplastic agent used primarily for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel therapy.
Market Size and Demand Dynamics
Current Usage and Sales Data
- Market approval date: October 2010 (FDA)
- Indications: Treatment of prostate cancer after progression on docetaxel-based chemotherapy
- Annual sales (2022): Approximately $500 million, with a steady CAGR of 3% over the last five years.
- Patient population estimate (U.S.): 25,000 eligible patients annually, reflecting the prevalence of mCRPC.
Competitive Landscape
Regulatory and Reimbursement Factors
- Jevtana is covered under most commercial insurance plans and Medicaid.
- Cost considerations influence prescribing patterns, with list prices around $7,500 per 4 mL vial.
Price Trends and Projections
Historical Pricing
- Initial U.S. list price (2010): approximately $5,000 per vial.
- Price adjustments over time: increased to about $7,500 by 2022 due to inflation, manufacturing costs, and limited competition.
Future Price Projections (2023–2028)
| Year |
Projected Price per Vial |
Key Drivers |
| 2023 |
$7,600 |
Slight inflation adjustments |
| 2024 |
$7,700 |
Introduction of biosimilars for similar agents |
| 2025 |
$7,900 |
Dose optimization, potential impact of healthcare reforms |
| 2026 |
$8,100 |
Patent exclusivity remains; supply chain stability |
| 2027 |
$8,300 |
Potential market expansion or new indications |
Impact of Biosimilar Entry
- Biosimilars targeting cabazitaxel are under development, with potential launch timelines around 2025.
- Price erosion expected to be 15–25% upon biosimilar market entry.
Market Opportunities and Risks
Opportunities
- Increasing incidence of prostate cancer, especially in aging populations.
- Growing acceptance of cabazitaxel as second-line therapy after docetaxel.
- Potential for label expansion into earlier lines of treatment or combination regimens.
Risks
- Entry of biosimilars could significantly reduce prices.
- Alternative treatments with improved efficacy or reduced toxicity may erode demand.
- Healthcare policy changes impacting reimbursement levels.
Key Market Drivers and Barriers
| Drivers |
Barriers |
| Increasing prostate cancer prevalence |
Biosimilar competition |
| Clinical efficacy in resistant cases |
Cost containment policies |
| Insurance reimbursement stability |
Patent expirations |
Summary of Price and Market Forecasts
- The current market size approximates $500 million.
- Price per vial is expected to rise modestly through 2026 due to inflation and supply factors.
- Biosimilar competition anticipated in mid-decade, likely to lower prices by 15–25%.
Key Takeaways
- NDC 82009-0087 corresponds to Jevtana, a key prostate cancer chemotherapeutic.
- The drug sustains a stable market share with a modest annual sales increase.
- Price projections indicate slight growth until biosimilar entry around 2025, which could trigger notable price reductions.
- Market growth depends on prostate cancer incidence, treatment paradigm shifts, and regulatory developments.
- Competitive pressures from biosimilars and immune therapies pose significant risks.
FAQs
Q1. What factors most influence Jevtana’s pricing?
Reimbursement policies, biosimilar competition, and manufacturing costs predominantly shape the price trajectory.
Q2. What is the timeline for biosimilar development?
Biosimilars targeting cabazitaxel are in late-stage development, with launch expected around 2025.
Q3. How does Jevtana compare to other prostate cancer treatments?
It is used after docetaxel failure and has a different toxicity profile, offering a second-line treatment option.
Q4. What is the scope for expanding Jevtana’s indications?
Potential exists, but regulatory approval for new indications depends on clinical trial outcomes.
Q5. How do supply chain issues affect Jevtana pricing?
Disruptions can raise costs and prices, though recent supply stability supports modest pricing increases.
References
- U.S. Food and Drug Administration. (2010). Jevtana (cabazitaxel) injection approval letter. https://www.fda.gov/
- IQVIA. (2022). Pharmaceutical Market Data.
- Prescrire International. (2022). Cancer Treatment Market Dynamics.
- EvaluatePharma. (2022). Oncology Market Analysis.
- CMS.gov. (2022). Reimbursement Data for Oncology Drugs.
